[
1. Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica. 1997;82:345-7.
]Search in Google Scholar
[
2. Pengo V. ISTH guidelines on Lupus Anticoagulant testing. Throm Res. 2012;130:S76-7. DOI: 10.1016/j.thromres.2012.08.28310.1016/j.thromres.2012.08.283
]Search in Google Scholar
[
3. Male C, Lechner K, Eichinger S, Kyrle PA, Kapiotis S, Wank H, et al. Clinical significance of lupus anticoagulants in children. J Pediatrics. 1999;134:199-205. DOI: 10.1016/S0022-3476(99)70416-610.1016/S0022-3476(99)70416-6
]Search in Google Scholar
[
4. Knobe K, Tedgård U, Ek T, Sandström PE, Hillarp A. Lupus anticoagulants in two children-bleeding due to nonphospholipid-dependent antiprothrombin antibodies. Eur J Pediatr. 2012 Sep;171(9):1383-7. DOI: 10.1007/s00431-012-1737-110.1007/s00431-012-1737-1
]Search in Google Scholar
[
5. Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Auto-immun. Feb-Mar 2014;48-49:20-5. DOI: 10.1016/j.jaut.2014.01.00610.1016/j.jaut.2014.01.006
]Search in Google Scholar
[
6. Desposito F, Arkel Y. Inhibitors of coagulation in children. Crit Rev Oncol Hematol. 1987;7(1):53-69. DOI: 10.1016/S1040-8428(87)80014-810.1016/S1040-8428(87)80014-8
]Search in Google Scholar
[
7. Moore GW. Current Controversies in Lupus Anticoagulant Detection. Antibodies (Basel). 2016 Dec 2;5(4):22. DOI: 10.3390/antib504002210.3390/antib5040022669884631558003
]Search in Google Scholar
[
8. Ames PRJ, Graf M, Archer J, Scarpato N, Iannaccone L. Prolonged activated partial thromboplastin time: Difficulties in discriminating coexistent factor VIII inhibitor and lupus anticoagulant. Clin Appl Thromb Hemost. 2015 Mar;21(2):149-54. DOI: 10.1177/107602961454151610.1177/107602961454151624989713
]Search in Google Scholar
[
9. Kallanagowdar C, Chauhan A, Puertolas MV, Warrier R. Prevalence and Resolution of Lupus Anticoagulant in Children. Ochsner J. 2016;16(2):172-5.
]Search in Google Scholar
[
10. Swadzba J, Iwaniec T, Pulka M, de Laat B, de Groot PG, Musial J. Lupus anticoagulant: Performance of the tests as recommended by the latest ISTH guidelines. J Thromb Haemost. 2011 Sep;9(9):1776-83. DOI: 10.1111/j.1538-7836.2011.04420.x10.1111/j.1538-7836.2011.04420.x21707912
]Search in Google Scholar
[
11. Ames PRJ, Montero D, Archer J. Co-existent Acquired Haemophilia and Lupus Anticoagulant. A Thorny Issue. Indian J Hematol Blood Transfus. 2016 Jun; 32(Suppl 1): 248. DOI: 10.1007/s12288-015-0572-810.1007/s12288-015-0572-8492551427408404
]Search in Google Scholar
[
12. Penmetsa GK, Rodgers GM, Smock KJ. Avoiding errors in the laboratory evaluation of potent lupus anticoagulants. Am J Hematol. 2010 Apr;85(4):272-4. DOI: 10.1002/ajh.2166610.1002/ajh.2166620196174
]Search in Google Scholar
[
13. Wincup C, Ioannou Y. The differences between childhood and adult onset antiphospholipid syndrome. Front Pediatr. 2018 Nov 27;6:362. DOI: 10.3389/fped.2018.0036210.3389/fped.2018.00362627779930542645
]Search in Google Scholar
[
14. Malbora B, Bilaloglu E. Lupus anticoagulant positivity in pediatric patients with prolonged activated partial thromboplastin time: A single-center experience and review of literature. Pediatr Hematol Oncol. 2015;32(7):495-504. DOI: 10.3109/08880018.2015.106530210.3109/08880018.2015.106530226383899
]Search in Google Scholar
[
15. Aguiar CL, Soybilgic A, Avcin T, Myones BL. Pediatric Antiphospholipid Syndrome. Curr Rheum Rep. 2015;17. DOI: 10.1007/s11926-015-0504-510.1007/s11926-015-0504-525854492
]Search in Google Scholar
[
16. Tagariello G, Radossi P, Salviato R, Zardo M, de Valentin L, Basso M, et al. Clinical relevance of isolated prolongation of the activated partial thromboplastin time in a cohort of adults undergoing surgical procedures. Blood Transf. 2017;15:557-61.
]Search in Google Scholar
[
17. Li R, Swaelens C, Vandermijnsbrugge F, Cantinieaux B. Applying a direct aPTT ratio (PlatelinLS/ActinFS) permits to identify rapidly and reliably a bleeding-related factor deficiency or a lupus anticoagulant sequential to an isolated prolongation of aPTT in paediatric pre-operative screening. Euro J Haematol. 2016;96:578-85. DOI: 10.1111/ejh.1263410.1111/ejh.1263426179977
]Search in Google Scholar
[
18. Devreese KMJ, Ortel TL, Pengo V, de Laat B. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16:809-13. DOI: 10.1111/jth.1397610.1111/jth.1397629532986
]Search in Google Scholar
[
19. Dreisbach JD, Dreisbach LP, Young DE, Dreisbach PB. Acquired factor VIII inhibitor and lupus anticoagulant presenting with prolonged aPTT: a case report. Grand Rounds. 2010;10:19-24.
]Search in Google Scholar
[
20. Brings HA, Waas JK, McCrae KR, Baele HR, Goldstone J. Successful management of life-threatening hemorrhage in a patient with synchronous lupus anticoagulant and factor VIII inhibitor. J Vasc Surg. 2002 Oct;36(4):853-5. DOI: 10.1067/mva.2002.12733610.1067/mva.2002.12733612368750
]Search in Google Scholar
[
21. Agostini V, Biasoli C, Biguzzi R, Santarelli R, Leoni P. Case Report: Coexistence of Factor VIII Inhibitor and Lupus Anticoagulant. Blood. 2007;110:3948. DOI: 10.1182/blood.V110.11.3948.394810.1182/blood.V110.11.3948.3948
]Search in Google Scholar
[
22. Ballard HS, Nyamuswa G. Life-threatening haemorrhage in a patient with rheumatoid arthritis and a lupus anticoagulant coexisting with acquired auto-antibodies against factor VIII. Br J Rheumatol. 1993 Jun;32(6):515-7. DOI: 10.1093/rheumatology/32.6.51510.1093/rheumatology/32.6.5158508289
]Search in Google Scholar
[
23. Seethala S, Collins NP, Comerci G. An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant. Case Rep Hematol 2013;2013:1-3. DOI: 10.1155/2013/52178510.1155/2013/521785380314024191205
]Search in Google Scholar
[
24. Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003;12:854-6. DOI: 10.1191/0961203303lu463cr10.1191/0961203303lu463cr14667103
]Search in Google Scholar
[
25. Tiede A, Werwitzke S, Scharf RE. Laboratory Diagnosis of Acquired Hemophilia A: Limitations, Consequences, and Challenges. Semin Thromb Hemost. 2014 Oct;40(7):803-11. DOI: 10.1055/s-0034-139000410.1055/s-0034-139000425299927
]Search in Google Scholar
[
26. Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus. 2014 Dec;23(14):1468-76. DOI: 10.1177/096120331454541010.1177/096120331454541025164304
]Search in Google Scholar
[
27. Sciascia S, Baldovino S, Schreiber K, Solfietti L, Radin M, Cuadrado MJ, et al. Thrombotic risk assessment in antiphospholipid syndrome: The role of new antibody specificities and thrombin generation assay. Clin Mol Allergy. 2016; 14:6. DOI: 10.1186/s12948-016-0043-210.1186/s12948-016-0043-2494736727429595
]Search in Google Scholar
[
28. Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, et al. The adjusted Global Antiphos-Pholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol. 2017 Aug 1;240:72-77. DOI: 10.1016/j.ijcard.2017.02.15510.1016/j.ijcard.2017.02.15528385357
]Search in Google Scholar